BridgeBio PharmaBBIO
Recorded

BridgeBio Pharma Jefferies Global Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 0Duration25 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Andrew TsaiSenior Biotech Analyst

Okay, we're going to get started. My name is Andrew Tsai, Senior Biotech Analyst at Jefferies. Thanks for joining us on day one of our London Healthcare Conference, and it's my pleasure to have the Co-founder and CEO of BridgeBio, Neil Kumar.

Neil KumarCo-founder and CEO

Welcome, Neil. Thank you, Andrew.

Andrew TsaiSenior Biotech Analyst

Maybe to start, you've obviously had a nice series of positive developments over the past year, or past two years, knock on wood. Talk about what you've accomplished, what you've achieved at BridgeBio so far, and walk us through the major milestones over the next year that could be helpful to level set our discussion.

Neil KumarCo-founder and CEO

Sure. Well, thanks again for the time, and thanks to Phil Ross as well for having us here at the conference again this year. As you say, BridgeBio is at a unique period right now because we have three impending launches in the next seven months or so, and that buttresses against now annualizing over $1 billion of ATTRUBY's growth, and we continue to focus there, both on the R&D side, as well as on the commercial side as well. Writ large, we have a launch hopefully in the next couple weeks in LGMD2I, which we can talk a little bit about. In February, we have an anticipated PDUFA for infigratinib for achondroplasia, and then shortly after that, PDUFA date for encaleret for use in ADH1.

Neil KumarCo-founder and CEO

We have several ongoing clinical trials. I think the biggest of which is our CHP phase III that should read out at the end of 2027, early 2028. Happy to talk about all of that and more as we go through.

Andrew TsaiSenior Biotech Analyst

Okay. To be clear, that's the hypoPTH- That's right.

Andrew TsaiSenior Biotech Analyst

trial. Okay. Perfect. I'll get to that.

Neil KumarCo-founder and CEO

Which I think is underappreciated.

Andrew TsaiSenior Biotech Analyst

Understood. Yeah. Okay. Starting with ATTRUBY, not too many questions because I do also want to focus on the pipeline today too, but to start with ATTRUBY.

Andrew TsaiSenior Biotech Analyst

The messaging has been to get first-line market share. I think you've guided to like 30%-40% at peak. Right now, maybe 25% plus type market share. I guess, why not more than that if your messaging is to have a superior stabilizer, and would you be, feel prepared to revise your peak sales penetration over time kind of thing?

Neil KumarCo-founder and CEO

Always prepared to do that. Most of our insights in and around peak year sales and share come from analogs, studies of analogs. We've studied about 1,040 different launches. We look at variance over time. It just tends to be, especially in the U.S., that if you're a second mover, you tend not to get more than 30%, 35% share. Obviously, we've outperformed that in Europe, where we're the leading brand. I think if all things were equal, we would be the leading brand in the U.S. as well, but all things are not equal, as you well know, just in terms of some of the different economics in the channel.

Neil KumarCo-founder and CEO

For us, it really starts with the clinical differentiation, and we're really now trying. Double-blind head-to-heads are not possible these days, so we're really trying to build that real-world evidentiary dataset to show superiority of acoramidis as it compares to tafamidis. Obviously, it's the only near-complete stabilizer, but building on that, you saw just two publications that we're quite proud of in the context of real-world evidence. One using Komodo data, which showed about a 34% relative risk reduction on hospitalization as compared to tafamidis, stat sig. The second was on Epic COSMOS, where we showed an 18% reduction in death and a 27% reduction in hospitalization, again, statistically significant as compared to tafamidis.

Neil KumarCo-founder and CEO

I think what's very heartening there is the large Ns associated with each of those studies, the statistical significance, and the early separation of those curves, congruent with what we're seeing in terms of the kidney signature, which we can get into as well. I think a lot of exciting science, and we're doubling down on R&D there as well. We just kicked off a cardiac remodeling phase IIIb/IV. We've got our ACT-EARLY primary prevention study. I think we're, of any of the sponsors, really doing more in terms of interrogating novel aspects of the medicine in terms of our phase IV studies.

Andrew TsaiSenior Biotech Analyst

Right. I find it notable in the real-world studies, I think it was a more contemporary population too.

Andrew TsaiSenior Biotech Analyst

That's right. The past two years, so I think that's notable.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day